In a landmark deal for China’s pharmaceutical industry, Haisco Pharmaceutical Group has signed a collaboration agreement with U.S. pharmaceutical giant Eli Lilly worth up to $3.054 billion, marking one of the largest international partnerships for a Chinese drugmaker and signaling growing global recognition of China’s innovative drug development capabilities.
Deal Overview: A Historic Partnership
On June 1, 2026, Haisco Pharmaceutical Group Co., Ltd. announced that its wholly-owned subsidiary, Haisco Pharmaceutical Technology (Lhasa) Co., Ltd., had signed an “Authorization and R&D Cooperation Agreement” with U.S. pharmaceutical leader Eli Lilly and Company on May 29, 2026. This agreement establishes a strategic partnership focused on innovative drug research and development across multiple disease areas.
The deal represents a milestone in China’s pharmaceutical industry evolution, demonstrating that Chinese companies can not only develop innovative drugs but also attract partnerships from global pharmaceutical leaders. The total potential value of up to $3.054 billion makes this one of the largest licensing deals involving a Chinese pharmaceutical company, rivaling major international transactions in the industry.
This partnership comes just one day after Haisco’s groundbreaking achievement of FDA approval for its innovative anesthetic Cipepofol, further cementing the company’s position as a leader in China’s pharmaceutical innovation landscape.
Deal Structure: How the Partnership Works
The collaboration agreement outlines a clear division of responsibilities and benefits between the two companies, structured to leverage each partner’s strengths.
Haisco’s Responsibilities
- Utilize its small molecule innovation technology platform
- Apply efficient new drug development capabilities
- Conduct discovery and early-stage research for up to five target projects selected by Eli Lilly
Eli Lilly’s Rights
- Global exclusive rights to developed projects, OR
- Exclusive rights outside mainland China, Hong Kong, Macau, and Taiwan
Haisco’s Retained Rights
- Exclusive rights in mainland China, Hong Kong, Macau, and Taiwan for selected projects
Financial Terms
| Component | Amount |
|---|---|
| Upfront and near-term payments | Up to $87 million |
| Milestone payments | Up to $2.967 billion |
| Sales royalties | Tiered royalties based on future net sales |
| Total potential value | Up to $3.054 billion |
Haisco’s Role: From Chinese Innovator to Global Partner
Haisco Pharmaceutical Group has established itself as one of China’s leading innovative pharmaceutical companies, with a strong track record in developing novel therapeutics. The company’s core strengths that attracted this partnership include:
Small Molecule Innovation Platform: Haisco has invested heavily in building world-class capabilities in small molecule drug discovery, enabling rapid identification and optimization of promising drug candidates.
Efficient Development Capabilities: The company has demonstrated ability to move drugs from discovery through clinical development efficiently, as evidenced by the recent FDA approval of Cipepofol, which progressed from Chinese approval to U.S. market entry in just six years.
Regulatory Expertise: Haisco has successfully navigated both Chinese and international regulatory pathways, with experience in conducting clinical trials that meet global standards.
The partnership validates Haisco’s strategic focus on “Innovation” and “Internationalization” — the same principles that guided the development of Cipepofol and other pipeline assets.
Eli Lilly’s Perspective: Betting on Chinese Innovation
For Eli Lilly, one of the world’s largest pharmaceutical companies with a market capitalization exceeding $700 billion, this partnership represents a strategic investment in Chinese innovation capabilities. The deal offers several advantages:
Access to Innovation: Lilly gains access to Haisco’s discovery platform and early-stage research capabilities, potentially accelerating its pipeline across multiple therapeutic areas.
Cost-Effective R&D: Partnering with Chinese companies can provide access to high-quality research at competitive costs compared to traditional Western drug discovery models.
Market Positioning: By allowing Haisco to retain Chinese rights, Lilly acknowledges the importance of the Chinese market while securing rights in the rest of the world.
Pipeline Expansion: The multi-target structure allows Lilly to diversify its pipeline risk across up to five different projects, increasing the probability of successful drug development.
This is not Lilly’s first investment in Chinese innovation — the company has been increasingly active in partnering with Chinese biotechnology companies, recognizing the growing sophistication of China’s pharmaceutical research capabilities.
Industry Significance: A Turning Point for Chinese Pharma
This partnership represents a significant inflection point for China’s pharmaceutical industry, signaling several important shifts:
From Generic to Innovative: For decades, China’s pharmaceutical industry was primarily known for manufacturing generic drugs. Deals like this demonstrate that Chinese companies have successfully transitioned to developing innovative therapeutics.
From Local to Global: Chinese pharmaceutical companies are increasingly becoming global players, not just in manufacturing but in innovation. This deal follows other recent successes including Cipepofol’s FDA approval and various licensing agreements with international partners.
Recognition of Quality: The willingness of a top-tier global pharmaceutical company to invest billions in Chinese research capabilities validates the quality and reliability of drug discovery work being conducted in China.
New Business Model: The deal demonstrates a new model for Chinese pharmaceutical companies — not just developing and selling their own drugs, but becoming research partners for global pharmaceutical leaders.
Industry analysts view this partnership as evidence that China’s pharmaceutical industry has reached a new level of maturity, capable of competing not just on cost but on innovation quality and speed.
Future Outlook: What This Means for Patients Worldwide
The Haisco-Lilly partnership has significant implications for patients and the global pharmaceutical landscape:
Accelerated Drug Development: The combination of Haisco’s discovery capabilities and Lilly’s development and commercialization expertise could accelerate the introduction of new treatments across multiple disease areas.
Increased Competition: The entry of Chinese innovative drugs into global markets may increase competition, potentially making treatments more accessible and affordable.
Global Research Collaboration: This partnership model may become more common, with Chinese companies increasingly contributing to global drug discovery efforts.
Chinese Patient Access: By retaining Chinese rights to certain projects, Haisco ensures that innovative treatments will be available to Chinese patients, potentially at more affordable prices than imported drugs.
Industry Evolution: The success of this partnership could encourage more Chinese pharmaceutical companies to invest in innovative research and seek international partnerships, further elevating China’s role in global healthcare innovation.
As the pharmaceutical industry becomes increasingly global, partnerships like this one between Haisco and Eli Lilly represent the future of drug development — collaborative, international, and focused on bringing innovative treatments to patients worldwide.